Hansa Biopharma AB (publ) announced that in its pre-clinical programs, NiceR next generation enzymes for repeat dosing. Development of Hansa's next generation enzymes for repeat dosing is progressing according to plan and initiation of IND-enabling toxocology studies is expected to commence in the first half of 2021. Imlifidase as pre-treatment ahead of gene therapy in DMD and LGMD.